Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction…
Read More
Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join…
Read More
